Please assess the completion status of the following clinical trial:

Trial Title: Acupuncture Point P6 Stimulation for Reduction of Nausea and Vomiting During Cesarean

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Female subjects ages 18 to 45~2. Subjects with American Society of Anesthesiologists (ASA) Class I or II~3. Subjects with elective primary or repeat cesarean delivery~4. Subjects who receive combined spinal epidural anesthesia~5. English and non-English speaking subjects will be included in the study~Exclusion Criteria:~1. Female subjects \<18 years of age~2. Subjects requiring emergent cesarean delivery~3. History of placenta accrete~4. Multiple gestation pregnancy~5. ASA status III or higher~6. Current history of pregnancy induced hypertension, pre-eclampsia, or eclampsia~7. History of any chronic medication use (other than prenatal vitamins), including inhaler medications~8. Current urinary tract infection, pneumonia, or otitis media

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Control (Type: NO_INTERVENTION): No anti-emetic medications and no acupuncture point P6 stimulation prior to administration of the standardized regional anesthesia
- Metoclopramide, Ondansetron (Type: ACTIVE_COMPARATOR): 10 mg Metoclopramide IV and 8 mg of Ondansetron IV immediately prior to administration of the standardized regional anesthesia
- Acupressure Point P6 stimulator (Type: EXPERIMENTAL): Acupuncture point P6 stimulation. This is a stimulation of the chi channel at the master of the heart (MH8 position) at the small depression of the volar surface of the distal right forearm just above the crest of the wrist. The device will be put on the patients in the operating room prior to administration of the regional anesthesia and will be removed after the cesarean section is complete.

Based on this trial design, predict the completion outcome and termination type (if applicable).